OBJECTIVE: The International Neuroblastoma Staging System (INSS) and Pathology Classification (INPC) were applied to analyze the results of treatment of 644 patients with neuroblastoma treated in Japan during the years from 1995 to 1999, and it was found that the pathology classification (INPC) showed the strongest relevance to prognosis compared to other factors such as stage, MYNC amplification, DNA ploidy and 1p-deletion. Current results of treatment for advanced neuroblastoma are still not satisfactory, so innovative therapeutic methods have been sought during the past 10 years. METHODS: Prospects for irinotecan and recombinant human endostatin (rhEndostatin) were studied expertimentally and clinically. RESULTS: Irinotecan is a water-soluble derivative of camptothecin, which is isolated from a Chinese tree, Camptotheca acuminata; Its effectiveness against neuroblastoma was confirmed by in vivo preclinical studies, and phase I clinical trials in Japan concluded the maximum tolerated dose of this agent is 160-180 mg/m2/day for 3 consecutive days, repeated after 25 days off. Phase II trials with this dose began, and we could obtain some encouraging results with the clinical use of irinotecan. rhEndostatin has been studied in in vivo experimental models. The action of rhEndostatin was quite different from those of other cytotoxic chemotherapeutic agents, and continuous administration of this substance showed a more marked anti-effect than its intermittent use. CONCLUSION: Irinotecan appears to be promising when it is given to the patients neuroblastoma, whereas rhEndostatin needs to have more preclinical studies before it is used in patients.
OBJECTIVE: The International Neuroblastoma Staging System (INSS) and Pathology Classification (INPC) were applied to analyze the results of treatment of 644 patients with neuroblastoma treated in Japan during the years from 1995 to 1999, and it was found that the pathology classification (INPC) showed the strongest relevance to prognosis compared to other factors such as stage, MYNC amplification, DNA ploidy and 1p-deletion. Current results of treatment for advanced neuroblastoma are still not satisfactory, so innovative therapeutic methods have been sought during the past 10 years. METHODS: Prospects for irinotecan and recombinant humanendostatin (rhEndostatin) were studied expertimentally and clinically. RESULTS:Irinotecan is a water-soluble derivative of camptothecin, which is isolated from a Chinese tree, Camptotheca acuminata; Its effectiveness against neuroblastoma was confirmed by in vivo preclinical studies, and phase I clinical trials in Japan concluded the maximum tolerated dose of this agent is 160-180 mg/m2/day for 3 consecutive days, repeated after 25 days off. Phase II trials with this dose began, and we could obtain some encouraging results with the clinical use of irinotecan. rhEndostatin has been studied in in vivo experimental models. The action of rhEndostatin was quite different from those of other cytotoxic chemotherapeutic agents, and continuous administration of this substance showed a more marked anti-effect than its intermittent use. CONCLUSION:Irinotecan appears to be promising when it is given to the patientsneuroblastoma, whereas rhEndostatin needs to have more preclinical studies before it is used in patients.
Authors: H M Katzenstein; A W Rademaker; C Senger; H R Salwen; N N Nguyen; P S Thorner; L Litsas; S L Cohn Journal: Clin Cancer Res Date: 1999-12 Impact factor: 12.531
Authors: K Kawa; N Ohnuma; M Kaneko; K Yamamoto; T Etoh; H Mugishima; M Ohhira; J Yokoyama; F Bessho; T Honna; J Yoshizawa; K Nakada; M Iwafuchi; T Nozaki; J Mimaya; T Sawada; T Nakamura; H Miyata; K Yamato; Y Tsuchida Journal: J Clin Oncol Date: 1999-10 Impact factor: 44.544
Authors: S Blaney; S L Berg; C Pratt; S Weitman; J Sullivan; L Luchtman-Jones; M Bernstein Journal: Clin Cancer Res Date: 2001-01 Impact factor: 12.531
Authors: J Thompson; W C Zamboni; P J Cheshire; L Lutz; X Luo; Y Li; J A Houghton; C F Stewart; P J Houghton Journal: Clin Cancer Res Date: 1997-03 Impact factor: 12.531
Authors: P J Houghton; P J Cheshire; J D Hallman; L Lutz; H S Friedman; M K Danks; J A Houghton Journal: Cancer Chemother Pharmacol Date: 1995 Impact factor: 3.333